Residual dysglycemia when at target HbA1c of 7% (53mmol/mol) in persons with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 104, Issue 3, 2014, Pages 370-375

  Monnier, L ^a   Colette, C ^a   Dejager, S ^b   Owens, D ^c  

^a UNIV MONTPELLIER   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Residual dysglycemia; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIET THERAPY; DYSGLYCEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

RESIDUAL DYSGLYCEMIA; TYPE 2 DIABETES;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 84902551724     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.03.012     Document Type: Article

References (28)

1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
2. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
3. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
4. American Diabetes Association Standards of Medical Care in Diabetes-2014. Diabetes Care 2014, 37(Suppl. 1):S14-S80.
5. IDF 2012 Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. doi:10.1016/j.diabres.2012.10.001.
6. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
7. Colagiuri S., Lee C.M.Y., Wong T.Y., Balkau B., Shaw J.E., Borch-Johnsen K., et al. Glycemic thresholds for diabetes-specific retinopathy. Implications for diagnostic criteria for diabetes. Diabetes Care 2011, 34:145-150.
8. 1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycemic thresholds. Diabetologia 2012, 55:636-643.
9. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2014, 37(Suppl. 1):S81-S90.
10. The Action to Control Cardiovascular Risk in Diabetes Study Group Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2445-2459.
11. Bonds D.E., Miller M.E., Bergenstal R.M., Buse J.B., Byington R.P., Cutler J.A., et al. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD Study. BMJ 2010, 340:b4909.
12. World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997, 277:925-926.
13. 1c measurement be reported. Diabetologia 2006, 49:7-10.
14. Sacks D.B., Bruns D.E., Goldstein D.E., Mac Laren N.K., Mc Donald J.M., Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (Position statement). Diabetes Care 2002, 25:750-786.
15. Sacks D.B. Measurements of hemoglobin A1c. A new twist on the part to harmony. Diabetes Care 2012, 35:2674-2680.
16. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
17. Monnier L., Colette C., Owens D. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther 2011, 13(Suppl. 1):S25-S32.
18. Dinneen S., Gerich J.E., Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992, 327:707-713.
19. Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia diabetes and cardiovascular events. Diabetes Care 2010, 33:1389-1394.
20. Monnier L., Wojtusciszyn A., Colette C., Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011, 13:813-818.
21. Cryer P.E. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med 2011, 124:993-996.
22. Mc Coy R.G., Van Houten H.K., Ziegenfuss J.Y., Shah N.D., Wermers R.A., Smith S.A. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012, 35:1897-1900.
23. 1c. Diabetes Care 2003, 26:881-885.
24. Peter R., Dunseath G., Luzio S.D., Owens D.R. Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes. Diabetes Metab 2013, 39:337-342.
25. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
26. Riddle M., Karl D.M. Individualizing targets and tactics for high risk patients with type 2 diabetes. Practical lessons from ACCORD and other cardiovascular trials. Diabetes Care 2012, 35:2100-2107.
27. Ahrén B., Leguizamo Dimas A., Miossec P., Saubadu S., Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013, 36:2543-2550.
28. Owens D.R., Monnier L., Bolli G.B. Differential effects of GLP-1 receptor agonists on components of dysglycemia in individuals with type 2 diabetes mellitus. Diabetes Metab 2013, 39:485-496.